Pharma companies fined over £3m in CMA nortriptyline probe

King Pharmaceuticals, Auden Mckenzie, Lexon (UK) and Alissa Healthcare broke the law in relation to nortriptyline supply, according to the Competitions and Markets Authority (CMA).

CMA.jpg
Two breaches of competition law were found, involving four pharmaceutical companies

An investigation into the supply of nortriptyline by four pharmaceutical companies found two breaches of competition law, resulting in fines of almost £3.4m, a payment of £1m to the NHS and the disqualification of a director of King Pharmaceuticals, the CMA announced yesterday (March 4).

Free to registered users

Register to gain full access to C+D and C+D Community content

Sign in or register for free

Latest from News

Retired pharmacist crushed to death in canal boat accident

 
• By 
 • comment

Margaret Billings sustained fatal injuries when she was caught between a moving boat and a riverbank during a day out “with family and friends”, an inquest has found.

NHSE scrapped: ‘Fresh start or just more political chaos?’

 
• By 
 • comment

C+D rounds up some of the immediate pharmacy reaction to news that NHS England will be abolished, with more control moving back to the government and local leaders…

New primary care medical director role as 2-year NHSE axing begins

 
• By 
 • comment

Wes Streeting has revealed that the DH is “immediately” working to scrap NHS England (NHSE) and put a new “transformation team” in place – adding that it is in the “very final stages” of concluding a new pharmacy contract deal.

More from Business

breaking news

IN FULL: Boots’ parent company sold in $24bn private equity deal

 
• By 
 • comment

Walgreens Boots Alliance (WBA) has “entered into a definitive agreement to be acquired” by private equity firm Sycamore Partners.

Jhoots accounts: Shareholder funds tumble while debts soar

 
• By 
 • comment

Jhoots Chemist’s accounts for 2024 have revealed an almost £2 million year-on-year dip in shareholder funds – as debts to creditors increase more than £2m.